Invitation to Idorsia's Full Year 2023 and Q1 2024 Financial Reporting webcast and conference call
May 14, 2024 11:45 ET
|
Idorsia Pharmaceuticals Ltd
Idorsia will publish its Full Year 2023 and Q1 2024 Financial Reporting on Tuesday May 21, 2024, at 07:00 CEST. An investor conference call and webcast will be held to discuss the results on the same...
Invitation to Idorsia's Full Year 2023 and Q1 2024 Financial Reporting webcast and conference call
May 14, 2024 11:45 ET
|
Idorsia Pharmaceuticals Ltd
Idorsia will publish its Full Year 2023 and Q1 2024 Financial Reporting on Tuesday May 21, 2024, at 07:00 CEST. An investor conference call and webcast will be held to discuss the results on the same...
Bondholders approve amended terms of the 2024 convertible bonds
May 06, 2024 12:35 ET
|
Idorsia Pharmaceuticals Ltd
Ad hoc announcement pursuant to Art. 53 LR Bondholders approve amended terms of the 2024 convertible bonds The proposed amendments to the terms of the 2024 convertible bond have been approved by the...
Bondholders approve amended terms of the 2024 convertible bonds
May 06, 2024 12:35 ET
|
Idorsia Pharmaceuticals Ltd
Ad hoc announcement pursuant to Art. 53 LR Bondholders approve amended terms of the 2024 convertible bonds The proposed amendments to the terms of the 2024 convertible bond have been approved by the...
Idorsia increases the consent fee in connection with the proposed restructuring of the 2024 convertible bond
May 01, 2024 12:00 ET
|
Idorsia Pharmaceuticals Ltd
Ad hoc announcement pursuant to Art. 53 LRThe proposed consent fee will be increased to 8’000’000 Idorsia shares. All other matters as proposed on April 23, 2024, remain unchanged.The bondholder...
Idorsia increases the consent fee in connection with the proposed restructuring of the 2024 convertible bond
May 01, 2024 12:00 ET
|
Idorsia Pharmaceuticals Ltd
Ad hoc announcement pursuant to Art. 53 LRThe proposed consent fee will be increased to 8’000’000 Idorsia shares. All other matters as proposed on April 23, 2024, remain unchanged.The bondholder...
JERAYGO (aprocitentan) recommended for approval in Europe for the treatment of resistant hypertension
April 26, 2024 01:00 ET
|
Idorsia Pharmaceuticals Ltd
Ad hoc announcement pursuant to Art. 53 LR Idorsia receives a positive opinion from the Committee for Medicinal Products for Human Use for JERAYGO™ (aprocitentan) as the first and only endothelin...
JERAYGO (aprocitentan) recommended for approval in Europe for the treatment of resistant hypertension
April 26, 2024 01:00 ET
|
Idorsia Pharmaceuticals Ltd
Ad hoc announcement pursuant to Art. 53 LR Idorsia receives a positive opinion from the Committee for Medicinal Products for Human Use for JERAYGO™ (aprocitentan) as the first and only endothelin...
Idorsia publishes an invitation to a bondholder meeting
April 23, 2024 01:00 ET
|
Idorsia Pharmaceuticals Ltd
Ad hoc announcement pursuant to Art. 53 LR A bondholder meeting will take place on May 6, 2024, to vote on proposals to amend the terms of the outstanding convertible bonds maturing on July 17, 2024,...
Idorsia publishes an invitation to a bondholder meeting
April 23, 2024 01:00 ET
|
Idorsia Pharmaceuticals Ltd
Ad hoc announcement pursuant to Art. 53 LR A bondholder meeting will take place on May 6, 2024, to vote on proposals to amend the terms of the outstanding convertible bonds maturing on July 17, 2024,...